These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32917983)

  • 1. Sepsis-associated severe interleukin-6 storm in critical coronavirus disease 2019.
    Huang L; Zhao X; Qi Y; Li H; Ye G; Liu Y; Zhang Y; Gou J
    Cell Mol Immunol; 2020 Oct; 17(10):1092-1094. PubMed ID: 32917983
    [No Abstract]   [Full Text] [Related]  

  • 2. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.
    Hou H; Zhang B; Huang H; Luo Y; Wu S; Tang G; Liu W; Mao L; Mao L; Wang F; Sun Z
    Clin Exp Immunol; 2020 Jul; 201(1):76-84. PubMed ID: 32365221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 and Hypercoagulability.
    Sholzberg M
    Clin Adv Hematol Oncol; 2020 Jul; 18(7):386-389. PubMed ID: 32903249
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm.
    Mahmoudi S; Rezaei M; Mansouri N; Marjani M; Mansouri D
    J Clin Immunol; 2020 Oct; 40(7):974-976. PubMed ID: 32648027
    [No Abstract]   [Full Text] [Related]  

  • 5. A plea for the pathogenic role of immune complexes in severe Covid-19.
    Vuitton DA; Vuitton L; Seillès E; Galanaud P
    Clin Immunol; 2020 Aug; 217():108493. PubMed ID: 32526273
    [No Abstract]   [Full Text] [Related]  

  • 6. Storm of soluble immune checkpoints associated with disease severity of COVID-19.
    Kong Y; Wang Y; Wu X; Han J; Li G; Hua M; Han K; Zhang H; Li A; Zeng H
    Signal Transduct Target Ther; 2020 Sep; 5(1):192. PubMed ID: 32895366
    [No Abstract]   [Full Text] [Related]  

  • 7. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19.
    Chen Y; Wang J; Liu C; Su L; Zhang D; Fan J; Yang Y; Xiao M; Xie J; Xu Y; Li Y; Zhang S
    Mol Med; 2020 Oct; 26(1):97. PubMed ID: 33121429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A proof of evidence supporting abnormal immunothrombosis in severe COVID-19: naked megakaryocyte nuclei increase in the bone marrow and lungs of critically ill patients.
    Roncati L; Ligabue G; Nasillo V; Lusenti B; Gennari W; Fabbiani L; Malagoli C; Gallo G; Giovanella S; Lupi M; Salviato T; Paolini A; Costantini M; Trenti T; Maiorana A
    Platelets; 2020 Nov; 31(8):1085-1089. PubMed ID: 32857624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan.
    Tu WJ; Cao J; Yu L; Hu X; Liu Q
    Intensive Care Med; 2020 Jun; 46(6):1117-1120. PubMed ID: 32253448
    [No Abstract]   [Full Text] [Related]  

  • 10. Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?
    Xi Y
    Signal Transduct Target Ther; 2020 Sep; 5(1):203. PubMed ID: 32934211
    [No Abstract]   [Full Text] [Related]  

  • 11. Immune characteristics of severe and critical COVID-19 patients.
    Yang L; Gou J; Gao J; Huang L; Zhu Z; Ji S; Liu H; Xing L; Yao M; Zhang Y
    Signal Transduct Target Ther; 2020 Aug; 5(1):179. PubMed ID: 32868756
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections.
    Remy KE; Mazer M; Striker DA; Ellebedy AH; Walton AH; Unsinger J; Blood TM; Mudd PA; Yi DJ; Mannion DA; Osborne DF; Martin RS; Anand NJ; Bosanquet JP; Blood J; Drewry AM; Caldwell CC; Turnbull IR; Brakenridge SC; Moldwawer LL; Hotchkiss RS
    JCI Insight; 2020 Sep; 5(17):. PubMed ID: 32687484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral and host factors related to the clinical outcome of COVID-19.
    Zhang X; Tan Y; Ling Y; Lu G; Liu F; Yi Z; Jia X; Wu M; Shi B; Xu S; Chen J; Wang W; Chen B; Jiang L; Yu S; Lu J; Wang J; Xu M; Yuan Z; Zhang Q; Zhang X; Zhao G; Wang S; Chen S; Lu H
    Nature; 2020 Jul; 583(7816):437-440. PubMed ID: 32434211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients.
    Chen L; Long X; Xu Q; Tan J; Wang G; Cao Y; Wei J; Luo H; Zhu H; Huang L; Meng F; Huang L; Wang N; Zhou X; Zhao L; Chen X; Mao Z; Chen C; Li Z; Sun Z; Zhao J; Wang D; Huang G; Wang W; Zhou J
    Cell Mol Immunol; 2020 Sep; 17(9):992-994. PubMed ID: 32620787
    [No Abstract]   [Full Text] [Related]  

  • 15. Is a "Cytokine Storm" Relevant to COVID-19?
    Sinha P; Matthay MA; Calfee CS
    JAMA Intern Med; 2020 Sep; 180(9):1152-1154. PubMed ID: 32602883
    [No Abstract]   [Full Text] [Related]  

  • 16. COVID-19-activated SREBP2 disturbs cholesterol biosynthesis and leads to cytokine storm.
    Lee W; Ahn JH; Park HH; Kim HN; Kim H; Yoo Y; Shin H; Hong KS; Jang JG; Park CG; Choi EY; Bae JS; Seo YK
    Signal Transduct Target Ther; 2020 Sep; 5(1):186. PubMed ID: 32883951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients.
    Urra JM; Cabrera CM; Porras L; Ródenas I
    Clin Immunol; 2020 Aug; 217():108486. PubMed ID: 32479985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphopenia during the COVID-19 infection: What it shows and what can be learned.
    Tavakolpour S; Rakhshandehroo T; Wei EX; Rashidian M
    Immunol Lett; 2020 Sep; 225():31-32. PubMed ID: 32569607
    [No Abstract]   [Full Text] [Related]  

  • 19. Cellular immune responses to covid-19.
    Sewell HF; Agius RM; Stewart M; Kendrick D
    BMJ; 2020 Jul; 370():m3018. PubMed ID: 32737031
    [No Abstract]   [Full Text] [Related]  

  • 20. Coagulopathy in COVID-19: Focus on vascular thrombotic events.
    Shi W; Lv J; Lin L
    J Mol Cell Cardiol; 2020 Sep; 146():32-40. PubMed ID: 32681845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.